Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. Mai 2026 11:15 ET | Quelle: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In...
30. Mai 2026 08:00 ET | Quelle: Cogent Biosciences, Inc.

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50,...
30. Mai 2026 08:00 ET | Quelle: Molecular Partners

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
30. Mai 2026 08:00 ET | Quelle: Replimune, Inc.

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
30. Mai 2026 08:00 ET | Quelle: https://immatics.com/

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer...
29. Mai 2026 19:15 ET | Quelle: Fitness Champs Holdings Limited

FCHL Receives Nasdaq Deficiency Notice on May 26, 2026

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- On May 26, 2026, Fitness Champs Holdings Limited (“Fitness Champs Holdings”, “FCHL” or the “Company”) (NASDAQ: FCHL), a distinguished aquatic sports...
29. Mai 2026 17:45 ET | Quelle: Clean Energy Technologies, Inc.

Clean Energy Technologies Receives Notice of Deficiency from Nasdaq

IRVINE, CA, May 29, 2026 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (Nasdaq: CETY) (“CETY” or the “Company”), a clean energy technology and solutions provider focused on converting waste...
29. Mai 2026 17:15 ET | Quelle: Celularity Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received...
29. Mai 2026 16:30 ET | Quelle: Gulf Resources, Inc.

Gulf Resources, Inc. Receives NASDAQ Notice to Late Filing of Its Quarterly Report

SHOUGUANG, China, May 29, 2026 (GLOBE NEWSWIRE) -- Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources,” “we,” or the “Company”), a leading manufacturer of bromine and crude salt in China, today...
29. Mai 2026 16:30 ET | Quelle: Recursion Pharmaceuticals

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026,...

Nächste Seite